Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

ANVISARegulator guidanceLot release and sample testingBiologicsHigh confidenceLast verified October 3, 2026

RDC 944/2024

Lot release procedure for vaccines and heterologous hyperimmune sera

Current edition

RDC 944 of November 28, 2024 (in force)

About this standard

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

No market listing is published yet.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: MHRA Responsible Person (import) guidance, EudraLex Volume 4 Annex 16, HC Lot Release Program guidance, TGA vaccine batch release, MFDS imported drug management regulation, MFDS national lot release regulation, RDC 669/2022, RDC 670/2022, RDC 900/2024, SFDA lot release policy, Taiwan biological product lot release regulations. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube